IDNA vs XBI

Key Takeaways

• IDNA targets companies benefiting from genomics, immunology, and bioengineering innovations with a concentrated portfolio of approximately 50 holdings and a higher expense ratio of 0.47%.
• XBI provides equal-weighted exposure to the U.S. biotechnology sector through roughly 160 holdings, emphasizing broad diversification within biotech and a lower expense ratio of 0.35%.
• Both ETFs focus on healthcare innovation but differ in geographic scope, with IDNA offering global exposure while XBI remains primarily U.S.-centric.
• IDNA exhibits higher concentration risk due to larger top holdings, whereas XBI's equal-weight methodology reduces single-stock dominance and supports more balanced sector representation.
• Structural differences position IDNA as a thematic play on emerging biotech technologies and XBI as a comprehensive vehicle for U.S. biotech market participation.
• Investors seeking cost efficiency and wider diversification may find XBI more aligned with broad sector exposure, while those prioritizing specific innovation themes may prefer IDNA.

Introduction

Investors evaluating targeted healthcare exposure often compare thematic and sector-specific exchange-traded funds (ETFs) like IDNA and XBI. These funds do not compete directly but instead offer complementary approaches within biotechnology and life sciences. IDNA emphasizes global companies positioned for long-term growth in genomics, immunology, and bioengineering, while XBI delivers broad access to the U.S. biotechnology industry through an equal-weighted index. The comparison helps investors understand differences in strategy, diversification, costs, and positioning amid ongoing innovation in drug development and personalized medicine.

iShares Genomics Immunology and Healthcare ETF (IDNA) Overview

The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index. This rules-based, passive strategy selects developed and emerging market companies that may benefit from advancements in genomics, immunology, and bioengineering. The fund typically holds around 50 securities, with significant allocations to health care. Top holdings often include Moderna Inc. (MRNA), Twist Bioscience Corp. (TWST), and Iovance Biotherapeutics Inc. (IOVA), reflecting concentration in innovative biopharmaceutical names. The expense ratio stands at 0.47%. IDNA maintains nearly 100% exposure to the health care sector and features a global footprint with primary weight in the United States and select developed markets. Rebalancing follows the underlying index methodology.

SPDR S&P Biotech ETF (XBI) Overview

The SPDR S&P Biotech ETF (XBI) tracks the S&P Biotechnology Select Industry Index using a passive, equal-weighted approach. This methodology assigns roughly equal importance to U.S. biotechnology companies across market capitalizations, resulting in approximately 160 holdings. Top positions typically represent about 2% each, including names such as Twist Bioscience Corp. (TWST), Moderna Inc. (MRNA), and Natera Inc. (NTRA). The expense ratio is 0.35%. XBI allocates nearly all assets to the biotechnology sub-industry within health care and maintains primarily domestic exposure. Quarterly rebalancing supports the equal-weight structure, promoting broader representation across small-, mid-, and large-cap biotech firms.

Industry and Thematic Backdrop

The biotechnology sector continues to evolve amid advances in gene editing, immunotherapy, and precision medicine. Capital flows into life sciences reflect sustained interest in innovation pipelines, supported by regulatory pathways for novel therapies and potential shifts in interest rate expectations that influence growth-oriented investments. Macroeconomic factors, including research and development spending and clinical trial outcomes, drive sector dynamics. Risks include high development failure rates, patent expirations, and policy changes affecting drug pricing and reimbursement. Both ETFs operate within this environment, where thematic exposure to emerging technologies and broad sector participation respond differently to earnings cycles and capital allocation trends in healthcare.

Performance and Positioning Comparison

In recent market cycles, IDNA's thematic focus has led to distinct volatility patterns tied to developments in genomics and immunology companies, while XBI's equal-weighted construction has provided smoother participation across the broader U.S. biotech landscape. Relative positioning highlights IDNA's sensitivity to innovation milestones and global supply chains versus XBI's alignment with domestic sector rotation and earnings breadth. During periods of biotech strength, XBI's diversification across more holdings has supported consistent exposure, whereas IDNA's concentration amplifies outcomes from select high-conviction names. Both funds exhibit elevated volatility compared to broad market benchmarks due to their healthcare emphasis, with differences stemming from geographic scope and weighting methodologies rather than short-term price fluctuations.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights into ETFs like IDNA and XBI can leverage this platform for efficient discovery.

Tickeron AI Verdict

Based on observable structural factors including lower expense ratio, greater number of holdings, and equal-weighted diversification that reduces concentration risk, Tickeron’s AI would currently assign a higher probabilistic preference to XBI for investors seeking broad U.S. biotech exposure. IDNA offers compelling thematic depth in genomics and immunology but carries higher costs and narrower holdings. The assessment weighs cost efficiency, diversification profile, and sector momentum without constituting investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations